Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036833 | 0.91 | L3MBTL1 (0.43) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 | |
| SCHEMBL1779630 | 0.89 | HTR6 (0.44) | L3MBTL1PTGDR2HTR6GSK3BEED | |
| SCHEMBL1778860 | 0.86 | PTGDR2 (0.34) | PTGDR2PCSK9HTR6PSEN1PSEN2 | |
| SCHEMBL1777351 | 0.84 | KDM4E (0.45) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 | |
| SCHEMBL1778220 | 0.84 | L3MBTL1 (0.40) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 | |
| SCHEMBL1779371 | 0.84 | PSEN1 (0.44) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 | |
| SCHEMBL6140206 | 0.84 | L3MBTL1 (0.47) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 | |
| SCHEMBL12606428 | 0.83 | L3MBTL1 (0.40) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 | |
| SCHEMBL1779250 | 0.83 | L3MBTL1 (0.40) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 | |
| SCHEMBL1777336 | 0.83 | L3MBTL1 (0.46) | L3MBTL1PTGDR2CCNE1CDK2PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990343-B1 | Azaindoles | AVENTIS PHARMA LTD (GB) | 2012-04-04 | — | — | EP | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1263759-B1 | AZAINDOLES | AVENTIS PHARMA LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7227020-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | L3MBTL1 2911/4885PTGDR2 1659/4885CCNE1 46/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | L3MBTL1 4557/4885PTGDR2 803/4885CCNE1 243/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | L3MBTL1 2911/4885PTGDR2 1357/4885CCNE1 42/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | L3MBTL1 4695/4885PTGDR2 1583/4885CCNE1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.